Post

FDA ‘green list’ flagging illegal GLP-1RA compounders is long overdue

In the midst of the rising popularity of glucagon-like peptide-1 receptor agonists (GLP-1RAs), and their compounded versions, the US Food …
Podcast: The FDA’s emerging aversion to advisory committees

Last month, the head of the US Food and Drug Administration's (FDA) Centre for Drug Evaluation and Research (CDER) George …
BMS expands CAR-T portfolio with $1.5bn Orbital buyout

Bristol Myers Squibb (BMS) has agreed to acquire CAR-T specialist Orbital Therapeutics for $1.5bn, adding several RNA-based therapies to the …
AstraZeneca sets $4.5bn Virginia API plant construction in motion

AstraZeneca has commenced construction of its $4.5bn active pharmaceutical ingredient (API) manufacturing facility in Virginia. The site, which is located near …
Flu vaccine uptake increases 28% in England

The number of people receiving a flu vaccine across England has increased by over a quarter, as cases of both …

FDA approves Teva and Medincell’s bipolar I disorder treatment

Teva Pharmaceuticals and Medincell have gained approval from the US Food and Drug Administration (FDA) for Uzedy (risperidone), a once-a-month …
FDA ‘green list’ flagging illegal GLP-1RA compounders is long overdue

In the midst of the rising popularity of glucagon-like peptide-1 receptor agonists (GLP-1RAs), and their compounded versions, the US Food …
Podcast: The FDA’s emerging aversion to advisory committees

Last month, the head of the US Food and Drug Administration's (FDA) Centre for Drug Evaluation and Research (CDER) George …
BMS expands CAR-T portfolio with $1.5bn Orbital buyout

Bristol Myers Squibb (BMS) has agreed to acquire CAR-T specialist Orbital Therapeutics for $1.5bn, adding several RNA-based therapies to the …
AstraZeneca sets $4.5bn Virginia API plant construction in motion

AstraZeneca has commenced construction of its $4.5bn active pharmaceutical ingredient (API) manufacturing facility in Virginia. The site, which is located near …
Flu vaccine uptake increases 28% in England

The number of people receiving a flu vaccine across England has increased by over a quarter, as cases of both …
FDA approves Celltrion’s Eydenzelt for eye diseases

Celltrion has received approval from the US Food and Drug Administration (FDA) for the biosimilar product, Eydenzelt (aflibercept-boav), to treat …
Pharma R&D set to endure despite rising MFN costs

Pharmaceutical research and development (R&D) is unlikely to be significantly impacted by most favored nation (MFN) pricing, according to industry …
Turbine and AstraZeneca partner for ADC discovery

Turbine and AstraZeneca have entered a partnership to enhance the discovery of antibody-drug conjugates (ADCs) using the former’s virtual disease …
Boehringer’s Jascayd nets first FDA IPF approval in over 10 years

Boehringer Ingelheim’s Jascayd (nerandomalist) has got the US Food and Drug Administration (FDA) nod in idiopathic pulmonary fibrosis (IPF), making …